Quantcast
Last updated on April 16, 2014 at 11:48 EDT

Latest Serotonin-norepinephrine reuptake inhibitor Stories

2009-01-13 17:55:55

The use of antidepressant medications by patients with fibromyalgia syndrome is associated with a reduction in pain, sleep disturbances and depressed mood and improvement of health-related quality of life, according to an analysis of previous studies, which is published in the January 14 issue of JAMA. Fibromyalgia syndrome (FMS), which consists of chronic widespread pain and tenderness, with other symptoms including fatigue and sleep difficulties, has an estimated prevalence of 0.5 percent...

2008-10-27 12:00:10

Eli Lilly and Company has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion on a Cymbalta application for the treatment of fibromyalgia. The Committee for Medicinal Products for Human Use (CHMP) received data on the use of duloxetine in the treatment of fibromyalgia in 1,411 patients in four placebo-controlled studies and 350 patients in one open-label safety study, a total of 1,761 patients in five clinical...

2008-10-24 06:00:05

INDIANAPOLIS, Oct. 24 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion on a Cymbalta(R) (duloxetine hydrochloride) application for the treatment of fibromyalgia. "Eli Lilly and Company and Boehringer Ingelheim are naturally disappointed by the CHMP's opinion," said James Russell, M.D., global medical director for duloxetine, Eli Lilly and Company. "We remain confident in the duloxetine...

2008-10-15 09:00:48

COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder (MDD) in adults. Desvenlafaxine has already been approved for the treatment of MDD in adults in the United States, Australia and Brazil, and applications are currently pending in 22 markets. As part of its global regulatory strategy, and in consultation with the Committee for...

2008-09-26 09:00:40

Adheris, Inc., a leader in patient adherence and education programs, announced today the results of a new study that examined adherence rates among patients on SSRI/SNRI antidepressant therapy. Study results showed that patients new to antidepressant treatment and those who had restarted therapy after a lapse of 6 or more months were twice as likely to discontinue therapy in the first 30 days of treatment versus patients previously dispensed an antidepressant. According to lead author...

2008-09-22 15:00:53

MONTCLAIR, N.J., Sept. 22 /PRNewswire/ -- The American Society of Pain Educators (ASPE) recently launched, the second of a three-part Webcast series: Is Your Persistent Chronic Pain Weighing You Down? at http://www.painawareness.org/. This Webcast addresses the importance of proper weight control in managing chronic pain. WHO: -- Inspirational testimony from Olympic Gold Medalist and chronic pain sufferer Nikki Stone. -- Practical pain management tips from Dr. Warren A. Katz, Clinical...

2008-08-22 03:00:10

To: MEDICAL EDITORS Contact: Charles McAtee, Eli Lilly and Company, +1-317-277-1566; or Eva Freitag, Boehringer Ingelheim, + 49 (6132) 77-2964 INDIANAPOLIS, Aug. 22 /PRNewswire-FirstCall/ -- Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD). This approval -- the fourth for duloxetine in Europe -- was issued on 28 July following an...

2008-07-24 09:01:13

The American Society of Pain Educators (ASPE) announces the launch of an educational Webcast series on chronic pain with leading health specialists and Olympic Games gold medalist and chronic pain sufferer, Nikki Stone. The first in the three-part series, "Keep Moving! Persistent Chronic Pain Doesn't Have to Hold You Back" is available today at www.painawareness.org. The first Webcast addresses the benefits of exercise for individuals with chronic pain and provides practical tips by leading...

2008-07-23 09:00:00

CHARLOTTE, N.C., July 23, 2008 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase II trial of Droxidopa, alone and in combination with carbidopa, for the treatment of Fibromyalgia. Fibromyalgia is a chronic and debilitating condition that is characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue,...

2008-06-27 03:00:35

INDIANAPOLIS, June 27 /PRNewswire-FirstCall/ -- Eli Lilly and Co and Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion supporting the approval of Cymbalta(R) (duloxetine hydrochloride) for the treatment of Generalised Anxiety Disorder (GAD). The positive opinion is based upon the results of five clinical studies -- four double-blind placebo-controlled studies and a...